From the Journals

Uptick in lung cancer in younger women, not related to smoking


 

  • Individuals aged 30-34 years in Canada, Denmark, and Germany.
  • Those aged 40-44 years in Germany, the Netherlands, and the United States.
  • Those aged 44-50 years in the Netherlands and the United States.
  • Those aged 50-54 years in Canada, Denmark, and New Zealand.

Countries with an insignificant crossover from male to female dominance of lung cancer were located across Africa, the Americas, Asia, Europe, and Oceania.

Again, incidence rates were typically characterized by falling rates of lung cancer among men in more recent birth cohorts, and lung cancer incidence trends were more variable in women.

The team writes: “Of note, the six countries demonstrating a significant crossover are among those considered to be more advanced in the tobacco epidemic.

“Many of the countries where the crossover was insignificant or when there was no crossover are considered to be late adopters of the tobacco epidemic, with the effects of the epidemic on the burden of lung cancer and other smoking-related diseases beginning to manifest more recently, or perhaps yet to come.”

They suggest that low- and middle-resource countries may not follow the tobacco epidemic pattern of high-income countries, and so “we may not see higher lung cancer incidence rates in women than men for the foreseeable future in these countries.”

No funding for the study has been disclosed. The authors have disclosed no relevant financial relationships.

This article first appeared on Medscape.com.

Pages

Recommended Reading

COPD adds complexity to shared decision making for LDCT lung cancer screening
Journal of Clinical Outcomes Management
Many institutions exceed recommended radiation doses during lung cancer screening
Journal of Clinical Outcomes Management
PACIFIC: Patterns of lung cancer progression suggest role for local ablative therapy
Journal of Clinical Outcomes Management
OS benefit with pembrolizumab endures long-term in advanced NSCLC
Journal of Clinical Outcomes Management
Cardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkers
Journal of Clinical Outcomes Management
Immunotherapy duo extends survival in first line for advanced NSCLC
Journal of Clinical Outcomes Management
Lung cancer screening, early diagnosis still lower among blacks, Hispanics
Journal of Clinical Outcomes Management
Not all lung cancer patients receive treatment
Journal of Clinical Outcomes Management
Patient-reported outcomes support first-line pembrolizumab for NSCLC
Journal of Clinical Outcomes Management
Global project reveals cancer’s genomic playbook
Journal of Clinical Outcomes Management